This activity has expired. Credit is no longer available.
This activity is supported by educational grants provided by Amgen, AstraZeneca, Celgene Corporation, Incyte Corporation, Merck Sharp & Dohme Corp., Takeda Oncology, Pharmacyclics LLC, an AbbVie Company, and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.
Risk-Adapted Treatment of Acute Myelogenous Leukemia
Jean A. Ridgeway, DNP, APN, NP-C, AOCN®
The University of Chicago Medicine
Acute myeloid leukemia is a heterogenous group of distinct malignancies that accounts for 80% of acute leukemias in adults. Recent advancements in diagnostic tests, such as next-generation sequencing, have led to the identification of unique biomarkers associated with acute myeloid leukemia. These advancements, along with new targeted therapies, offer hope for a greater impact of survival for patients with this disease.
|
|
These activities, certified for CME/CE/CPE credit, are jointly provided by
  |